CSL - CSL Limited
- Thread starter kaisong
- Start date
-
- Tags
- csl csl limited
Country Lad
Off into the sunset
- Joined
- 11 July 2005
- Posts
- 1,640
- Reactions
- 1,684
Knobby22
Mmmmmm 2nd breakfast
- Joined
- 13 October 2004
- Posts
- 10,613
- Reactions
- 8,275
I'm in the same boat. Can't sell many till I retire. Capital gains tax would crush me.
galumay
learner
- Joined
- 17 September 2011
- Posts
- 3,661
- Reactions
- 2,541
There are worse problems to have, mate!!
Good evening Knobby22
pay the tax over a rum... ha ha ha ha ha
Buy more and sell again .... pay more tax ... drink more rum ahhhhhhhh vicious circle really ....
but the joy of it all ...Have a good weekend bloke
Kind regards
rcw1
Dona Ferentes
Did the Thessalonians write back?
- Joined
- 11 January 2016
- Posts
- 20,009
- Reactions
- 27,536
AFR
Before Paul McKenzie became chief executive of CSL in March 2023, he spent almost four years as chief operating officer, a good chunk of which was spent helping the company navigate the supply chain problems created by the pandemic.
McKenzie adopted what might be called the traditional CSL approach to problem-solving: think long-term, and invest accordingly. And the $US3 billion that the company subsequently spent building redundancy and resiliency in its supply chain in the United States suddenly looks like money well spent, as President Donald Trump’s tariff policies upend global trade.
“When other people stopped investing, we continued to invest,” McKenzie tells Chanticleer on Monday. “It was important for me, when I came in as chief operating officer, to make sure that we had this redundancy around the world.”
It’s that redundancy that McKenzie now thinks can help CSL play both sides of the vicious trade war between the US and China, which escalated again on Sunday...
...
When it comes to Behring’s plasma-based products, which account for 66 per cent of CSL’s group revenue, McKenzie thinks CSL has a strong argument that what it sells in America is made in America – it collects plasma in the US, and it fractionates (medical jargon for separating plasma into components) in the US.
“That’s really consistent with the administration’s objectives,” McKenzie says. “So this really should preclude those products from being subject to any future potential tariffs, even when they institute them for the pharmaceutical sector, because the majority of the value is derived in the US.”
He makes a similar argument for the Seqirus business, which accounts for 18 per cent of group revenue; CSL produces more than 100 million doses of flu vaccine at its facility in North Carolina’s Holly Springs, which is enough to supply the vast majority of the US market.
“We live up to what the US administration is looking to do – large investments over the last several years and a large percentage of our employees there.”
.
....The threat posed by specific US tariffs for the pharmaceutical sector is still to play out, but McKenzie is confident there is an acknowledgement in the US of both the importance of CSL’s products and its supply chains. The needs of patients are not going away – the past flu season has been particularly nasty, with 550,000 hospitalisations and 170 pediatric deaths – and McKenzie is confident CSL can make the case to the Trump administration that it is a vital part of the American healthcare sector.
“Having medically relevant products is the key, and I think it’s really important for us to make sure people understand that,” he says. “It’s a really noisy period for lots of industries, and our industry specifically. But for me, working with multiple governments around the world year in and year out, it’s a matter of just making sure we keep those governments focused on how they get these critical medicines to patients."
Before Paul McKenzie became chief executive of CSL in March 2023, he spent almost four years as chief operating officer, a good chunk of which was spent helping the company navigate the supply chain problems created by the pandemic.
McKenzie adopted what might be called the traditional CSL approach to problem-solving: think long-term, and invest accordingly. And the $US3 billion that the company subsequently spent building redundancy and resiliency in its supply chain in the United States suddenly looks like money well spent, as President Donald Trump’s tariff policies upend global trade.
“When other people stopped investing, we continued to invest,” McKenzie tells Chanticleer on Monday. “It was important for me, when I came in as chief operating officer, to make sure that we had this redundancy around the world.”
It’s that redundancy that McKenzie now thinks can help CSL play both sides of the vicious trade war between the US and China, which escalated again on Sunday...
...
When it comes to Behring’s plasma-based products, which account for 66 per cent of CSL’s group revenue, McKenzie thinks CSL has a strong argument that what it sells in America is made in America – it collects plasma in the US, and it fractionates (medical jargon for separating plasma into components) in the US.
“That’s really consistent with the administration’s objectives,” McKenzie says. “So this really should preclude those products from being subject to any future potential tariffs, even when they institute them for the pharmaceutical sector, because the majority of the value is derived in the US.”
He makes a similar argument for the Seqirus business, which accounts for 18 per cent of group revenue; CSL produces more than 100 million doses of flu vaccine at its facility in North Carolina’s Holly Springs, which is enough to supply the vast majority of the US market.
“We live up to what the US administration is looking to do – large investments over the last several years and a large percentage of our employees there.”
.
....The threat posed by specific US tariffs for the pharmaceutical sector is still to play out, but McKenzie is confident there is an acknowledgement in the US of both the importance of CSL’s products and its supply chains. The needs of patients are not going away – the past flu season has been particularly nasty, with 550,000 hospitalisations and 170 pediatric deaths – and McKenzie is confident CSL can make the case to the Trump administration that it is a vital part of the American healthcare sector.
“Having medically relevant products is the key, and I think it’s really important for us to make sure people understand that,” he says. “It’s a really noisy period for lots of industries, and our industry specifically. But for me, working with multiple governments around the world year in and year out, it’s a matter of just making sure we keep those governments focused on how they get these critical medicines to patients."
JohnDe
La dolce vita
- Joined
- 11 March 2020
- Posts
- 4,941
- Reactions
- 7,371
Australian pharmaceutical major CSL is eyeing boosting manufacturing of its lifesaving plasma and vaccine products from its existing operations in the US as it looks to navigate the threat of US President Donald Trump turning his attention to the healthcare sector.
Chief executive Paul McKenzie believes there is enough “redundancy and resiliency” in CSL’s global supply chain to shift production and should bypass the prospect of tariffs across about 85 per cent of his US businesses.
CSL expects its lifesaving medicines and plasma to escape Donald Trump’s tariff net
CSL says it has invested heavily in building out its US manufacturing footprint in recent years. Picture: CSL
Australian pharmaceutical major CSL is eyeing boosting manufacturing of its lifesaving plasma and vaccine products from its existing operations in the US as it looks to navigate the threat of US President Donald Trump turning his attention to the healthcare sector.
Chief executive Paul McKenzie believes there is enough “redundancy and resiliency” in CSL’s global supply chain to shift production and should bypass the prospect of tariffs across about 85 per cent of his US businesses.
The homegrown pharma makes blood plasma products, high-end vaccines and more recently has moved into dialysis and treatment of kidney diseases.
However, McKenzie conceded the final 10 per cent of his US sales are across advanced kidney treatment products that are mostly imported from CSL’s European businesses, and this will need to be worked through.
“For almost 85 per cent of the (US) business, the majority of what we do is generate its value in the US,” McKenzie told The Australian.
“Our footprint in the US is quite significant. We’ve invested multiple billions of dollars over the last couple of years. We can respond very well to these policy initiatives.
“We’ll see what happens with Section 232 (tariffs). We’ll participate in the process, but we feel for these reasons and the medical necessity of our products for people in public health, we should be in good stance.”
CSL is one of the world’s biggest influenza vaccine manufacturers with hi-tech plants in Victoria, North Carolina and the UK.
Its blood processing plants are also in Australia, the US and Europe.
The US is by far CSL’s biggest market and generates about 50 per cent of its sales there, mostly from its Behring blood products and collections business.
CSL is one of the world’s biggest suppliers of blood and derived products to governments, including US health authorities.
The comments by McKenzie, who has just returned to Melbourne after several weeks in the US, underscore the grey area in which many global pharmas now find themselves.
Trump initially spared the pharma industry and medicines from his “Liberation Day” tariff announcement, but last week he threatened that he planned to announce a “major” tariff on pharmaceutical imports shortly.
The sector has been bracing for Mr Trump to use the sector-specific Section 232 tariffs that he has slapped on steel imports and cars.
However, with the market turmoil prompting a 90-day pause on reciprocal tariffs, the pharmaceutical companies remain in the dark about when or how they could be targeted. CSL’s shares had been off nearly 10 per cent on the initial tariff uncertainty, although with the weekend exemption on high-end tech manufactured in China, the market is hopeful there is more wiggle room than thought.
CSL shares jumped 2.1 per cent on Monday.
The risk for Trump in slapping tariffs on pharma is creating supply shortages in lifesaving drugs and treatment. The supply chains are complex and often involve importing critical compounds that are finished in the US.
Some blood-related products are finished at the new CSL factory in Melbourne’s north. Picture: Tim Carrafa
Even CSL has complex plasma-related products derived from blood collections in the US and are partially processed in Australia, before being returned to the US.
With a market value of more than $115bn, CSL is Australia’s biggest pharma, and it spends more than $1bn annually on research and development.
McKenzie said most of the processing is generated in the US, but where some plasma-derived proteins are collected in the US but processed outside the country, he expected that their critical role in saving lives should see them fall outside the tariff net.
The former CSL chief operating officer who took charge two years ago, McKenzie said one of the big lessons from the Covid-19 pandemic was to build “redundancy and resiliency in our supply chain”, which gives the company additional capacity to shift production around the world.
This is why all manufacturers are looking at their supply chains to ensure they can continue operations without disruption.
McKenzie also revealed that CSL is seeking to fast track approvals from Chinese authorities to supply albumin there from its new $900m plasma fractionation plant at Broadmeadows, in Melbourne’s north.
Currently CSL’s albumin sales from China are sourced from multiple plants in Europe or the US.
CSL’s new $900m factory in Broadmeadows is looking to export albumin products to China. Picture: Tim Carrafa
Albumin is used in emergencies to treat blood loss and restore rapidly falling blood pressure.
“We are planning to look to prevent disruptions in the normal supply chain. We have a brand new facility in Broadmeadows. This month we are about ready to file for approval in China. So this is a good example, I’m hoping, that we can work with the regulatory agencies in China and Australia that would certainly shore up the critical supply of albumin, but our ability to supply from multiple nodes,” McKenzie said.
“This is something that we do as a course of business.”
Even if the tariff wall goes up, McKenzie says this is unlikely to impact CSL’s $1.6bn-plus R&D budget. The company has had a long-term target of about 10 per cent of revenue invested in R&D, and much of this is spent in Australia. Although research also takes place in the US and Europe.
“For us, the world is our lab, and I think it’s really important to make sure you continue to access great innovation everywhere.
“We have a proud history of accessing innovation here in Australia, equally accessing it in Europe and the US, and we’ll continue to do that.
“However where CSL could start thinking differently over the longer term is how it is using its multiple manufacturing facilities.”
Before joining CSL in 2019, McKenzie worked with global names from Johnson & Johnson and Biogen.
He says it’s too early to tell what the disruption of tariffs is likely to represent for the pharma industry. Although the Covid pandemic represents the biggest disruption for the sector by far.
“Not only from a supply chain, but the redirecting of dollars towards trying to solve that problem,” he said.
“Our job is to continue to work with administrations around the world to deliver medicines. From a CSL viewpoint our 100-year history is about resiliency and making a difference for patients. I think we’re in good shape across the majority of our businesses.”
Knobby22
Mmmmmm 2nd breakfast
- Joined
- 13 October 2004
- Posts
- 10,613
- Reactions
- 8,275
CSL still slowly dropping I believe it's fear of tariffs and recession and vaccine hesitancy. Ugly graph.
17% drop over last 6 months.
17% drop over last 6 months.
- Joined
- 20 July 2021
- Posts
- 13,658
- Reactions
- 18,999
the numbers don't attract me , but those that bought in years back should be cruising ( and grinning )
rcw1 quadruple gorilla swing trade, buy average $232.80 …
Have another tranche captured at $245 in drawer …
| Confirmation Number | Order Number | Trade Date | Buy/ Sell | Security | Units | Average Price ($) | Brokerage (inc GST.) | Net Proceeds ($) | Settlement Date | Confirmation Status | Download Confirmation |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 161728835 | N200280536 | 2/05/2025 | S | CSL | 200 | 255.800 | 61.39 | 51,098.61 | 6/05/2025 | Confirmed | D |
DrBourse
If you don't Ask, You don't Get.
- Joined
- 14 January 2010
- Posts
- 969
- Reactions
- 2,347
I first bought CSL’s woes to the faithful CSL followers in dozens of posts beginning 16/4/24 right through till early 2025 when it became obvious that CSL’s LT Trend would be Down to at least $242, and probably to $223. Those Posts Started @ Post #254 Page 13 in the forum DrB TA Help for Beginners – and in the CSL Forum for about the same periods).
CSL has been stuck just above or just below $242 for the past 25 trading days.
So it is reassuring to see that Australian Experts are finally putting 2 & 2 together.
The following is from Market Index/ChartWatch dated 13/5/25 @ 9.15am.
“”A "value trap" is a stock that appears cheap based on traditional valuation metrics like low price-to-earnings ratio ("PE ratio") or price-to-book ratios etc. but continues to underperform or decline. Investors may be drawn into thinking the stock is undervalued, only to discover that the company faces deeper structural issues — such as declining industry relevance, poor management, or unsustainable earnings.
Is CSL a value trap? It hardly meets the traditional definition of low PE ratio given it's trading at 20.3 times earnings on a on a 12-month forward basis according to Goldman Sachs. Hardly what you'd call bargain basement! Consider though, investors have always paid a premium for CSL's superior growth and quality. To this end, Goldman's also notes that CSL's current PE ratio is a massive 31% discount to its 10-year average.
CSL is the cheapest it's been in 10-years, yet it finds itself lodged in today's Downtrends Scan List — as a Feature Downtrend no less! As popular as CSL is with the big brokers (10 out of 11 of them we've surveyed have a buy-or-equivalent rating), it's short and long term trends are well and truly stuck in the down position.
Indeed, in spite of all of those buy recommendations, CSL has made Feature Downtrend 22 times since 27 September last year when it entered at a closing price of $285.10.
ChartWatch Scans doesn't prognosticate, it's based on a trend following model. So I have no idea where CSL's share price will be in the next 8 months — simply that despite the brokers, and despite its valuation, right now — there's more supply than demand for CSL shares””.
The next level down for CSL is to abt $175.45 – I’m not saying CSL will get to that level, but it sure looks interesting.
CSL has been in decline since 12/2/24, and in Serious Decline since 1/8/24 IMO, and CSL have not improved in areas like Financials, and announcements of the foot’n’mouth variety are still appearing.
Gunna get off my CSL Soap Box now.
DrB.
CSL has been stuck just above or just below $242 for the past 25 trading days.
So it is reassuring to see that Australian Experts are finally putting 2 & 2 together.
The following is from Market Index/ChartWatch dated 13/5/25 @ 9.15am.
“”A "value trap" is a stock that appears cheap based on traditional valuation metrics like low price-to-earnings ratio ("PE ratio") or price-to-book ratios etc. but continues to underperform or decline. Investors may be drawn into thinking the stock is undervalued, only to discover that the company faces deeper structural issues — such as declining industry relevance, poor management, or unsustainable earnings.
Is CSL a value trap? It hardly meets the traditional definition of low PE ratio given it's trading at 20.3 times earnings on a on a 12-month forward basis according to Goldman Sachs. Hardly what you'd call bargain basement! Consider though, investors have always paid a premium for CSL's superior growth and quality. To this end, Goldman's also notes that CSL's current PE ratio is a massive 31% discount to its 10-year average.
CSL is the cheapest it's been in 10-years, yet it finds itself lodged in today's Downtrends Scan List — as a Feature Downtrend no less! As popular as CSL is with the big brokers (10 out of 11 of them we've surveyed have a buy-or-equivalent rating), it's short and long term trends are well and truly stuck in the down position.
Indeed, in spite of all of those buy recommendations, CSL has made Feature Downtrend 22 times since 27 September last year when it entered at a closing price of $285.10.
ChartWatch Scans doesn't prognosticate, it's based on a trend following model. So I have no idea where CSL's share price will be in the next 8 months — simply that despite the brokers, and despite its valuation, right now — there's more supply than demand for CSL shares””.
The next level down for CSL is to abt $175.45 – I’m not saying CSL will get to that level, but it sure looks interesting.
CSL has been in decline since 12/2/24, and in Serious Decline since 1/8/24 IMO, and CSL have not improved in areas like Financials, and announcements of the foot’n’mouth variety are still appearing.
Gunna get off my CSL Soap Box now.
DrB.
Good evening,
David Wilson has nearly four decades of stockmarket experience and is currently the deputy head of Australian equities growth at First Sentier and in charge of the firm’s $10 billion Geared Australian Share Fund.
Contained with an article by Joanne Tran AFR on 12 May 2025:
According to Wilson,... not all companies get it right. One business currently in need of a reset, is blood plasma giant CSL.
“CSL needs to recover its mojo,” he says. “The Vifor acquisition was very disappointing and reduced the confidence of investors in the company. But the underlying blood products business is still a world-leading operation. It just needs to come back into focus.”
Wilson adds that while CSL’s vaccines business is more volatile, it’s been well managed overall – “they’ve done a solid job there. The real problem was the acquisition. But I think they’ve now recognised that, and the next step is re-establishing its earnings momentum.”
Holding
Kind regards
rcw1
David Wilson has nearly four decades of stockmarket experience and is currently the deputy head of Australian equities growth at First Sentier and in charge of the firm’s $10 billion Geared Australian Share Fund.
Contained with an article by Joanne Tran AFR on 12 May 2025:
According to Wilson,... not all companies get it right. One business currently in need of a reset, is blood plasma giant CSL.
“CSL needs to recover its mojo,” he says. “The Vifor acquisition was very disappointing and reduced the confidence of investors in the company. But the underlying blood products business is still a world-leading operation. It just needs to come back into focus.”
Wilson adds that while CSL’s vaccines business is more volatile, it’s been well managed overall – “they’ve done a solid job there. The real problem was the acquisition. But I think they’ve now recognised that, and the next step is re-establishing its earnings momentum.”
Holding
Kind regards
rcw1
DrBourse
If you don't Ask, You don't Get.
- Joined
- 14 January 2010
- Posts
- 969
- Reactions
- 2,347
Hi rcw, M8, CSL have more problems other than those few mentioned above.
Such as an improved and believable set of Financials.
Then they have to find a cure for their regular Foot in Mouth announcements.
Then they have to stop the Analysts continuous & stupid Target Price calls of $350+.
A hint, $223.55, $211.04, then $175.45.
Sorry to be so blunt M8, but that needed 2B put into the CSL arena.
DrB.
Garpal Gumnut
Ross Island Hotel
- Joined
- 2 January 2006
- Posts
- 15,007
- Reactions
- 13,336
Mate, agree totally, if CSL ever reach $350 I'll be a willing seller ! Brokers are like Real Estate agents.
gg
DrBourse
If you don't Ask, You don't Get.
- Joined
- 14 January 2010
- Posts
- 969
- Reactions
- 2,347
The general public lost faith in CSL abt 2 years ago, that's just general knowledge.
The other 2 anomalies are that, the sheep lost faith in CSL abt 12 mths ago, and the really big anomalie is that the Analysts/Brokers continue to ramp CSL, that really makes the Analysts & Brokers look like they are out of the loop.
I know one of the reasons why the Analysts & Brokers continue to push CSL, they all have their own "Proprietory Analysing Systems", each one is slightly different.
For example,
"Broking Houses receive Briefings directly from Companies, the problem with that is that the Broking houses then somehow manage to ‘embellish’ those briefing figures to ridiculous levels, they manage to use words like, "our proprietary model suggests, we have lifted our FY earnings by 15%, we have lifted our segment volumes by 17%, we expect, we anticipate, we calculate, we project, we predict, we estimated, we believe, we see signs, etc, etc"...... AND they often use other words such as, Planned, Scheduled, Intends, Potential, Nominal, Conceptional, etc, etc....
Each Analyst/Broker has their own versions of 'how to calculate an IV,..... then, for example – one broker uses a proprietary analytic framework that helps clients uncover value, adjusting for distortions and ambiguities created by local accounting regulations....... It adjusts EPS for one-time events, capitalizes operating leases (where their use is significant), and converts inventory from LIFO costing to a FIFO basis, and also emphasizes the separation of operating performance of a company from its financing for a more complete view of how a company generates earnings....... "
Broking Houses can’t be seen to just relay the Co Briefings ‘word for word’ as the Companies quote them – that would render the Brokers Reports as “useless repetition”......
IMO, Brokers Exist only to make you "BROKER"......
The reason my analysis is different to that of others, is that I rely on FACTS.
I do not employ a proprietary model OR any proprietary analytic framework, as they would only distort the raw facts.
Don’t blindly follow anyone’s Guesstimates, Do Your Own Research.....
DrB
- Joined
- 17 April 2025
- Posts
- 143
- Reactions
- 269
Not Held (too big for me)
Under $240 heading down again??
Under $240 heading down again??
Good morning
CSL today (17/06/25) has revealed it will launch its Andembry medication for a rare, genetic disorder in the US following approval by the US Food and Drug Administration. Andembry helps prevent attacks of hereditary angioedema (HAE), which causes potentially life-threatening swelling in the body. It is the first and only treatment targeting factor XIIa, a key enzyme, for prophylactic use to provide sustained protection from attacks of HAE in adult and pediatric patients aged 12 years and older. HAE occurs in about 1 in 50,000 people of any ethnic group.
A pivotal placebo-controlled Phase 3 Vanguard trial and its open-label extension study showed Andembry reduced the median number of HAE attacks by more than 99 per cent.
The medication is approved in Australia, the UK, the European Union, Japan, Switzerland and United Arab Emirates.
Kind regards
rcw1
CSL today (17/06/25) has revealed it will launch its Andembry medication for a rare, genetic disorder in the US following approval by the US Food and Drug Administration. Andembry helps prevent attacks of hereditary angioedema (HAE), which causes potentially life-threatening swelling in the body. It is the first and only treatment targeting factor XIIa, a key enzyme, for prophylactic use to provide sustained protection from attacks of HAE in adult and pediatric patients aged 12 years and older. HAE occurs in about 1 in 50,000 people of any ethnic group.
A pivotal placebo-controlled Phase 3 Vanguard trial and its open-label extension study showed Andembry reduced the median number of HAE attacks by more than 99 per cent.
The medication is approved in Australia, the UK, the European Union, Japan, Switzerland and United Arab Emirates.
Kind regards
rcw1
DrBourse
If you don't Ask, You don't Get.
- Joined
- 14 January 2010
- Posts
- 969
- Reactions
- 2,347
C'mon CSL - Dive to $223.55, you know you can do it, it's where you belong, down there a LOOOONG Way from the Mythical $350.00....
- Joined
- 11 May 2025
- Posts
- 1,169
- Reactions
- 1,324
Dr Have you thought about changing your Photo from a Bull to a Bear?
